Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s REC-4881 has shown “strong and durable” efficacy in ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock is a Buy.

From the moment you meet, you feel as though you’ve known them before. There’s an instant connection, almost as if you’ve been drawn together by an invisible force. It’s intoxicating, addictive, and ...

India, Dec. 21 -- Congress Lok Sabha MP Karti Chidambaram said he has no regrets about not knowing Hindi, stating that he never had the opportunity to learn the language and that there was no ...

Have a question about dating, relationships, or just love in general? Cosmo has answers. Consider this page a safe space to find expert-approved advice on how to navigate all the modern issues of the ...